TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 366138

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30912681

Group type: EXPERIMENTAL
Intervention: Experienced instructor
Number of subjects: 74

Group type: COMPARATOR
Intervention: Novice instructor
Number of subjects: 74
Study: 27974169

Group type: EXPERIMENTAL
Intervention: Antibiotics-first treatment (intravenous ertapenem for ≥48 hours, followed by oral cefdinir and metronidazole)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antibiotics-first treatment
Number of subjects: 30
Study: 25881079

Group type: EXPERIMENTAL
Intervention: vandetanib
Number of subjects: 944

Group type: COMPARATOR
Intervention: comparator
Number of subjects: 944
Study: 24039797

Group type: EXPERIMENTAL
Intervention: Complementary food supplements containing multiple vitamins and minerals provided daily for 1.5 years.
Number of subjects: 250
Study: 21435103

Group type: EXPERIMENTAL
Intervention: Fat infusion (F)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Carbohydrate infusion (C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Protein infusion (P)
Number of subjects: 24
Study: 19517420

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 31

Group type: COMPARATOR
Intervention: Menses phase
Number of subjects: 31
Study: 17577004

Group type: EXPERIMENTAL
Intervention: NNT outcome for heart attacks (NNT of 13 patients to prevent 1 heart attack)
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Large postponement for some patients (8 months for 1 of 4 patients)
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Short postponement for all patients (2 months)
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: NNT outcome for hip fractures (NNT of 57 patients to prevent 1 fracture)
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Large postponement for some patients (16 months for 3 of 100 patients)
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Short postponement for all patients (16 days)
Number of subjects: 2754
Study: 14762367

Group type: EXPERIMENTAL
Intervention: Iloprost (6-24 ng.kg(‐1).min(‐1))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (10 patients with normal platelet counts and no previous extended exposure to heparin)
Number of subjects: 32
Study: 11182008

Group type: EXPERIMENTAL
Intervention: Electronic peak flow meter (actual data)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Written diary (reported data)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (comparison of data)
Number of subjects: 40
Study: 9517521

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg three times daily for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 1333617

Group type: EXPERIMENTAL
Intervention: Clonidine (dose not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study: 3901730

Group type: EXPERIMENTAL
Intervention: Liquid monopolar electrocoagulation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 78
Study: 30107469

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 36)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 46
Study: 28631347

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 18
Study: 26248590

Group type: EXPERIMENTAL
Intervention: Insulin pump therapy (CSII)
Number of subjects: 18
Study: 24838896

Group type: EXPERIMENTAL
Intervention: Papacarie Duo(®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-speed bur
Number of subjects: 20
Study: 23232168

Group type: EXPERIMENTAL
Intervention: Betahistine Chloride (BC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Epley maneuver (rehabilitation treatment)
Number of subjects: 96
Study: 19318477

Group type: EXPERIMENTAL
Intervention: Ipilimumab (anti-CTLA-4 monoclonal antibody)
Number of subjects: 0
Study: 18019593

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program
Number of subjects: 54
Study: 15464318

Group type: EXPERIMENTAL
Intervention: Risk score based on eight variables (hypotension, intra‐aortic balloon pump, congestive heart failure, chronic kidney disease, diabetes, age >75 years, anemia, and volume of contrast)
Number of subjects: 8357

Group type: EXPERIMENTAL
Intervention: Risk score model applied in validation dataset
Number of subjects: 8357
Study: 11256871

Group type: EXPERIMENTAL
Intervention: Nonhormonal interventions for menopause symptoms
Number of subjects: 61
Study: 9849693

Group type: EXPERIMENTAL
Intervention: G‐CSF starting on day +1
Number of subjects: 37

Group type: COMPARATOR
Intervention: G‐CSF starting on day +7
Number of subjects: 37
Study: 7889637

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg sustained release daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Verapamil (240 mg sustained release daily)
Number of subjects: 29
Study: 2924043

Group type: EXPERIMENTAL
Intervention: Behavioural contracting
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Point systems
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Point systems plus response costs
Number of subjects: 2
Study: 209485

Group type: EXPERIMENTAL
Intervention: 4 mg estradiol valerate (single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dosages of estrogens
Number of subjects: 0
Study: 29642743

Group type: EXPERIMENTAL
Intervention: Weekly problem‐based sessions led by psychologists over 3 months
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Modified intervention led by psychologists over 9 months
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 166
Study: 31188153

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted paramedian spinal anaesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Landmark-guided paramedian spinal anaesthesia
Number of subjects: 80
Study: 26625194

Group type: EXPERIMENTAL
Intervention: Combined strategy (early surgical haemostasis, mechanical pressure on uterine wall, intrauterine balloon tamponade)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combined strategy
Number of subjects: 119
Study: 26163031

Group type: EXPERIMENTAL
Intervention: Intraosseous anaesthesia delivered by the computerised QuickSleeper system
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional infiltration anaesthesia
Number of subjects: 160
Study: 24115188

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg/day) plus lovastatin (30 mg/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 68
Study: 21817061

Group type: EXPERIMENTAL
Intervention: EGJ distension
Number of subjects: 10

Group type: COMPARATOR
Intervention: No EGJ distension (control)
Number of subjects: 10
Study: 22253983

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17115389

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study: 15518603

Group type: EXPERIMENTAL
Intervention: Thrombolysis In Myocardial Infarction (TIMI) risk score (TRS)
Number of subjects: 3801
Study: 10955034

Group type: EXPERIMENTAL
Intervention: Therapy focusing on reversing the underlying disorder and providing supportive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific tests
Number of subjects: 0
Study: 9244023

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Paracetamol 325 mg/dextropropoxyphene hydrochloride 32.5 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Paracetamol 500 mg/codeine phosphate 30 mg
Number of subjects: 75
Study: 8143995

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with folinic acid 200 mg/m2 plus 5-fluorouracil 400 mg/m2, intravenously, on days 1-5 every 4 weeks for 12 cycles
Number of subjects: 239

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 239
Study: 3260554

Group type: EXPERIMENTAL
Intervention: Ionic contrast media (sodium meglumine and amidotrizoate)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium (iohexol)
Number of subjects: 46
Study: 31216210

Group type: EXPERIMENTAL
Intervention: Videoconference psychotherapy (VC)
Number of subjects: 207

Group type: COMPARATOR
Intervention: In-person psychotherapy (IP)
Number of subjects: 207
Study: 31279324

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 29231320

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Western medication (carbamazepine)
Number of subjects: 90
Study: 25447041

Group type: EXPERIMENTAL
Intervention: Continuous external chest compressions plus continuous oxygen insufflation (C‐CPR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard‐CPR (S‐CPR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: C‐CPR
Number of subjects: 7
Study: 23134408

Group type: EXPERIMENTAL
Intervention: TAC with 6 months steroids withdrawal (6M SW)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: TAC with 3 months steroids withdrawal (3M SW)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: TAC with 14 days steroids withdrawal (14d SW)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: TAC with basiliximab induction and steroids avoidance (Bas SA)
Number of subjects: 502

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 502
Study: 21536090

Group type: EXPERIMENTAL
Intervention: IL-6 polymorphisms (-174G/C, -572G/C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subgroup analyses by ethnicity and quality score
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Meta-regression analysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall conclusion of the meta-analysis
Number of subjects: 30
Study: 19499294

Group type: EXPERIMENTAL
Intervention: C4‐6 laminoplasty preserving the C7 spinous process and its attached muscles (group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: C4‐7 laminoplasty (group B)
Number of subjects: 43
Study: 16616449

Group type: EXPERIMENTAL
Intervention: Stomp Out Smokes (SOS)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Brief Office Intervention (BOI)
Number of subjects: 139
Study: 15199653

Group type: EXPERIMENTAL
Intervention: Medication and psychoeducation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Medication without psychoeducation
Number of subjects: 52
Study: 11300428

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) 400 microg sublingual
Number of subjects: 11
Study: 9378379

Group type: EXPERIMENTAL
Intervention: Atropine (15 micrograms/kg intravenous bolus and 4 micrograms/kg/h maintenance dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 10
Study: 7506179

Group type: EXPERIMENTAL
Intervention: nimesulide
Number of subjects: 99

Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 99
Study: 3535012

Group type: EXPERIMENTAL
Intervention: Cisapride 8 mg intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisapride 1 mg atropine pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbachol 250 micrograms subcutaneously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily (1-week treatment)
Number of subjects: 0
Study: 28921241

Group type: EXPERIMENTAL
Intervention: DHEA 6.5 mg
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: DHEA 3.25 mg
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: DHEA 6.25 mg
Number of subjects: 464

Group type: COMPARATOR
Intervention: Plain moisturizer (PM)
Number of subjects: 464
Study: 26046585

Group type: EXPERIMENTAL
Intervention: 50 ml of water
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 500 ml of water
Number of subjects: 17
Study: 25013997

Group type: COMPARATOR
Intervention: NNC0195‐0092 (0.01‐0.32 mg/kg) single dose
Number of subjects: 105

Group type: COMPARATOR
Intervention: NNC0195‐0092 (0.02‐0.24 mg/kg) once-weekly doses for 4 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 23975746

Group type: EXPERIMENTAL
Intervention: Sevelamer-HCl
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both phosphate binders
Number of subjects: 40
Study: 22052374

Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance (BIA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deuterium Dilution Method (DDM)
Number of subjects: 40
Study: 18474811

Group type: EXPERIMENTAL
Intervention: Anakinra (150 mg s.c.)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 23

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 23
Study: 17176380

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy‐Adolescent Skills Training (IPT‐AST)
Number of subjects: 41

Group type: COMPARATOR
Intervention: School Counseling (SC)
Number of subjects: 41
Study: 14600860

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% with sufentanil 0.5 microg/ml
Number of subjects: 30
Study: 11124070

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Time-of-flight MR angiography
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 40

Group type: COMPARATOR
Intervention: Catheter angiography
Number of subjects: 40
Study: 8869862

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (group 1: 0.3 mg.kg‐1 i.v. bolus, 0.12 mg.kg‐1.h‐1 i.v. infusion)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (group 2: 0.5 mg.kg‐1 i.v. bolus, 0.24 mg.kg‐1.h‐1 i.v. infusion)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Heparin (150 IU.kg‐1 i.v. bolus, 20 IU.kg‐1.h‐1 i.v. infusion)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 61
Study: 1905293

Group type: EXPERIMENTAL
Intervention: Jobs Program (intervention)
Number of subjects: 0
Study: 7118065

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (40 mg p.o.)
Number of subjects: 0
Study: 31860110

Group type: EXPERIMENTAL
Intervention: Educational intervention delivered to mothers including information on sleep characteristics, improvements in the environment, establishment of a nighttime sleep routine, and waiting before attending nocturnal awakenings.
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Educational intervention delivered to mothers.
Number of subjects: 586

Group type: COMPARATOR
Intervention: Control group received counseling on breastfeeding benefits and written material on breastfeeding.
Number of subjects: 586
Study: 28093204

Group type: EXPERIMENTAL
Intervention: Chin symphysis bone plus allogeneic bone material plus leukocyte‐ and platelet‐rich fibrin (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iliac bone graft (Group B)
Number of subjects: 20
Study: 25005108

Group type: EXPERIMENTAL
Intervention: Eruption Guidance Appliance (EGA) for 1 year
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no orthodontic treatment)
Number of subjects: 48
Study: 24256083

Group type: EXPERIMENTAL
Intervention: BRV 20 mg/day
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: BRV 100 mg/day
Number of subjects: 399

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 399
Study: 21386714

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Medication (control)
Number of subjects: 24
Study: 19864243

Group type: EXPERIMENTAL
Intervention: CIN diagnosis reclassification by pathologists
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: CIN diagnosis with threshold at CIN 2
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: CIN diagnosis with threshold at CIN 3
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: CIN 2 diagnosis
Number of subjects: 1003
Study: 16979857

Group type: EXPERIMENTAL
Intervention: Clustered nursing care (CC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 90
Study: 14688156

Group type: EXPERIMENTAL
Intervention: 50 IU of recombinant FSH daily and GnRH antagonist Ganirelix 0.25 mg per day
Number of subjects: 66

Group type: COMPARATOR
Intervention: 50 IU of recombinant FSH on alternate days and GnRH antagonist Ganirelix 0.25 mg per day
Number of subjects: 66
Study: 11682380

Group type: EXPERIMENTAL
Intervention: Isoflurane (1.3% in air and oxygen)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2.0% in air and oxygen)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Conscious baseline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Depressor test sensitivity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pressor test sensitivity
Number of subjects: 20
Study: 9626173

Group type: EXPERIMENTAL
Intervention: Defibrillator therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medications alone (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transvenous defibrillators (alternative scenario)
Number of subjects: 0
Study: 8165081

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine emulsion (EMLA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo emulsion
Number of subjects: 180

Group type: COMPARATOR
Intervention: Music distraction
Number of subjects: 180
Study: 2835195

Group type: EXPERIMENTAL
Intervention: Enalapril maleate (10 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 14
Study: 29412378

Group type: EXPERIMENTAL
Intervention: Diabetes educational program (group education, home visit, telephone intervention)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control group (individual monitoring)
Number of subjects: 470
Study: 28266949

Group type: EXPERIMENTAL
Intervention: venlafaxine 75 mg + hypnosis (VH)
Number of subjects: 71

Group type: COMPARATOR
Intervention: venlafaxine 75 mg + sham hypnosis (VSH)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: placebo pill + hypnosis (PH)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: placebo pill + sham hypnosis (PSH)
Number of subjects: 71
Study: 26245216

Group type: EXPERIMENTAL
Intervention: Intensified IFX regimen (n = 36)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Personalized treatment defined by IFX and anti‐IFX antibodies (n = 33)
Number of subjects: 69
Study: 23503738

Group type: EXPERIMENTAL
Intervention: Stationary cycling
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Exercise and walking programme
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 87
Study: 21515591

Group type: EXPERIMENTAL
Intervention: Concerto (automatic left ventricular output management algorithm)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Consulta (automatic management of atrial, right ventricular and LV voltage)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Consulta
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Concerto and Consulta
Number of subjects: 739

Group type: COMPARATOR
Intervention: Sentry (manual voltage adjustments)
Number of subjects: 739
Study: 19078952

Group type: EXPERIMENTAL
Intervention: ASA404 plus carboplatin and paclitaxel (ASA404-CP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 73
Study: 16804124

Group type: EXPERIMENTAL
Intervention: Free amino acid solutions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized oral meal (healthy volunteers)
Number of subjects: 0
Study: 14674505

Group type: EXPERIMENTAL
Intervention: Citric acid 10% followed by 5% NaOCl for 2 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maleic acid 10% followed by 5% NaOCl for 2 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5% Oxalic acid followed by 5% NaOCl for 2 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 35% Phosphoric acid followed by 5% NaOCl for 2 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24% EDTA gel followed by 5% NaOCl for 2 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no etching agent and/or NaOCl solution)
Number of subjects: 0
Study: 11009265

Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol (group II, n = 208, 254 lesions) for 6 months
Number of subjects: 409

Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine (group I, n = 201, 240 lesions) for 1 month
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol (group II) in diabetic patients
Number of subjects: 409

Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine (group I) in diabetic patients
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol (group II)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine (group I)
Number of subjects: 409
Study: 8818065

Group type: EXPERIMENTAL
Intervention: Eat Smart School Nutrition Program (CATCH)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 59
Study: 1581367

Group type: EXPERIMENTAL
Intervention: Compliance-enhancement intervention group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment control group
Number of subjects: 40
Study: 6146180

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (150 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 30791871

Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Design strategies to maximize recruitment and retention
Number of subjects: 282
Study: 28236978

Group type: EXPERIMENTAL
Intervention: Patritumab plus erlotinib
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 212